Iomab-B Makes Actinium Pharma A Rare And Exciting Investment Opportunity

Further evidence of high KOL support for Iomab-B can be found simply by looking at the centers participating in SIERRA. The BMT market in the U.S. is highly concentrated. There are roughly 150 BMT centers in the country and the top 30 centers perform 50% of all the AML BMT procedures. Actinium is targeting the top 15-20 sites for enrollment, with 11 sites currently active and recruiting patients as of today. In March 2017, Actinium announced that data from SIERRA would qualify for registration in the EU. In May, management received approval to open the first clinical site in Canada. These announcements are a testament of the excellent credibility of the program.

(Click on image to enlarge)

What's Next For Actinium

The slide below shows the expected timeline for further updates on the SIERRA trial. SIERRA is expected to enroll 150 patients with 1:1 randomization between Iomab-B and physician's choice standard of care. As noted above, target participation for SIERRA is 15-20 clinical sites. That means an additional 4-9 sites are expected to open patient recruitment in the next few months. A data monitoring committee (DMC) is monitoring results from the trial and will be providing an update back to Actinium once the first 25% of patients receive treatment. That is expected to take place during the second half of the year.

(Click on image to enlarge)

View single page >> |

Disclaimer: BioNap is NOT an Investment Advisor. We are an investor intelligence and strategic advisory firm. Most of the companies mentioned on this blog are party to a services ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.